File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Adjunctive Mood Stabilizer and Benzodiazepine Use in Older Asian Patients with Schizophrenia, 2001-2009

TitleAdjunctive Mood Stabilizer and Benzodiazepine Use in Older Asian Patients with Schizophrenia, 2001-2009
Authors
KeywordsAsia
Benzodiazepines
Mood Stabilizers
Older Patients
Prescription Patterns
Schizophrenia
Issue Date2012
PublisherGeorg Thieme Verlag. The Journal's web site is located at http://www.thieme.de/pharmaco
Citation
Pharmacopsychiatry, 2012, v. 45 n. 6, p. 217-222 How to Cite?
AbstractObjective: This study surveyed the use of adjunctive mood stabilizers (MS) and benzodiazepines (BZD) in older Asian schizophrenia patients and examined their demographic and clinical correlates. Method: Information on hospitalized schizophrenia patients aged 55 years or more were extracted from the database of the Research on Asian Psychotropic Prescription Patterns (REAP) study. A total of 1 452 patients from 9 Asian countries and territories was included in the study. The patients' sociodemographic and clinical characteristics and the prescriptions of antipsychotics, MS and BZD were recorded using a standardized protocol and data collection procedure. Results: The frequency of MS prescription was 26.7% in the pooled sample, with 25.5% in 2001, 26.9% in 2004 and 27.7% in 2009. The corresponding figures for BZD were 20.7%, 20.2%, 18.4% and 23.1%, respectively. Multiple logistic regression analysis of the whole sample revealed that patients on MS were younger and more likely to be men and to have extrapyramidal side effects (EPS) and a longer duration of illness. Compared to patients in China, those in Japan were more likely to receive MS, while Korean patents were prescribed less MS. In contrast, there were no significant sociodemographic or clinical correlates of BZD use. Compared to patients in China, their Korean and Singaporean counterparts were more likely to be on BZD. Conclusions: The use of MS and BZD is not uncommon in older Asian patients with schizophrenia. Given the paucity of empirical data on the efficacy of these agents in individuals with schizophrenia of any age and concerns about added side effects in older patients in particular, the rationale for the prescription of these agents in this population warrants further examination. © Georg Thieme Verlag KG.
Persistent Identifierhttp://hdl.handle.net/10722/171978
ISSN
2023 Impact Factor: 3.6
2023 SCImago Journal Rankings: 0.834
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorXiang, YTen_US
dc.contributor.authorDickerson, Fen_US
dc.contributor.authorKreyenbuhl, Jen_US
dc.contributor.authorUngvari, GSen_US
dc.contributor.authorWang, CYen_US
dc.contributor.authorSi, TMen_US
dc.contributor.authorLee, EHMen_US
dc.contributor.authorHe, YLen_US
dc.contributor.authorChiu, HFKen_US
dc.contributor.authorYang, SYen_US
dc.contributor.authorChong, MYen_US
dc.contributor.authorTan, CHen_US
dc.contributor.authorKua, EHen_US
dc.contributor.authorFujii, Sen_US
dc.contributor.authorSim, Ken_US
dc.contributor.authorYong, MKHen_US
dc.contributor.authorTrivedi, JKen_US
dc.contributor.authorChung, EKen_US
dc.contributor.authorUdomratn, Pen_US
dc.contributor.authorChee, KYen_US
dc.contributor.authorSartorius, Nen_US
dc.contributor.authorShinfuku, Nen_US
dc.date.accessioned2012-10-30T06:19:08Z-
dc.date.available2012-10-30T06:19:08Z-
dc.date.issued2012en_US
dc.identifier.citationPharmacopsychiatry, 2012, v. 45 n. 6, p. 217-222en_US
dc.identifier.issn0176-3679en_US
dc.identifier.urihttp://hdl.handle.net/10722/171978-
dc.description.abstractObjective: This study surveyed the use of adjunctive mood stabilizers (MS) and benzodiazepines (BZD) in older Asian schizophrenia patients and examined their demographic and clinical correlates. Method: Information on hospitalized schizophrenia patients aged 55 years or more were extracted from the database of the Research on Asian Psychotropic Prescription Patterns (REAP) study. A total of 1 452 patients from 9 Asian countries and territories was included in the study. The patients' sociodemographic and clinical characteristics and the prescriptions of antipsychotics, MS and BZD were recorded using a standardized protocol and data collection procedure. Results: The frequency of MS prescription was 26.7% in the pooled sample, with 25.5% in 2001, 26.9% in 2004 and 27.7% in 2009. The corresponding figures for BZD were 20.7%, 20.2%, 18.4% and 23.1%, respectively. Multiple logistic regression analysis of the whole sample revealed that patients on MS were younger and more likely to be men and to have extrapyramidal side effects (EPS) and a longer duration of illness. Compared to patients in China, those in Japan were more likely to receive MS, while Korean patents were prescribed less MS. In contrast, there were no significant sociodemographic or clinical correlates of BZD use. Compared to patients in China, their Korean and Singaporean counterparts were more likely to be on BZD. Conclusions: The use of MS and BZD is not uncommon in older Asian patients with schizophrenia. Given the paucity of empirical data on the efficacy of these agents in individuals with schizophrenia of any age and concerns about added side effects in older patients in particular, the rationale for the prescription of these agents in this population warrants further examination. © Georg Thieme Verlag KG.en_US
dc.languageengen_US
dc.publisherGeorg Thieme Verlag. The Journal's web site is located at http://www.thieme.de/pharmacoen_US
dc.relation.ispartofPharmacopsychiatryen_US
dc.subjectAsiaen_US
dc.subjectBenzodiazepinesen_US
dc.subjectMood Stabilizersen_US
dc.subjectOlder Patientsen_US
dc.subjectPrescription Patternsen_US
dc.subjectSchizophreniaen_US
dc.titleAdjunctive Mood Stabilizer and Benzodiazepine Use in Older Asian Patients with Schizophrenia, 2001-2009en_US
dc.typeArticleen_US
dc.identifier.emailLee, EHM:edwinlhm@hku.hken_US
dc.identifier.authorityLee, EHM=rp01575en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1055/s-0031-1301292en_US
dc.identifier.pmid22290203-
dc.identifier.scopuseid_2-s2.0-84866389809en_US
dc.identifier.hkuros206198-
dc.identifier.isiWOS:000309321300002-
dc.publisher.placeGermanyen_US
dc.identifier.scopusauthoridXiang, YT=35241398400en_US
dc.identifier.scopusauthoridDickerson, F=7003825018en_US
dc.identifier.scopusauthoridKreyenbuhl, J=6602795669en_US
dc.identifier.scopusauthoridUngvari, GS=7006092063en_US
dc.identifier.scopusauthoridWang, CY=54925448700en_US
dc.identifier.scopusauthoridSi, TM=6701400479en_US
dc.identifier.scopusauthoridLee, EHM=7406967099en_US
dc.identifier.scopusauthoridHe, YL=54922035700en_US
dc.identifier.scopusauthoridChiu, HFK=54924876500en_US
dc.identifier.scopusauthoridYang, SY=54927263300en_US
dc.identifier.scopusauthoridChong, MY=7102632108en_US
dc.identifier.scopusauthoridTan, CH=7402817882en_US
dc.identifier.scopusauthoridKua, EH=7006748699en_US
dc.identifier.scopusauthoridFujii, S=7401814463en_US
dc.identifier.scopusauthoridSim, K=8513485500en_US
dc.identifier.scopusauthoridYong, MKH=47161681100en_US
dc.identifier.scopusauthoridTrivedi, JK=7005836490en_US
dc.identifier.scopusauthoridChung, EK=7202734618en_US
dc.identifier.scopusauthoridUdomratn, P=6602459819en_US
dc.identifier.scopusauthoridChee, KY=36100061600en_US
dc.identifier.scopusauthoridSartorius, N=7102159482en_US
dc.identifier.scopusauthoridShinfuku, N=7003855366en_US
dc.identifier.issnl0176-3679-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats